In addition, the serum survivin level was much higher in patients with PDAC at advanced stages and those with recurrence and poor differentiation; no significant differences in the serum levels of survivin were found in PDAC patients with different ages, genders, and tumor sizes. Here, BIRC5 is linked to neoplasm.